

1fw

Patent Application
Attorney Docket No. PC25421A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 30th day of November 2004.

By

Judi H. Licause

(Signature of person mailing)

Judi H. Licause

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Coe, et al. :

APPLICATION NO.: 10/791,984 : Examiner: Not Yet Assigned

FILING DATE: March 3, 2004 : Group Art Unit: 1614

TITLE: A PHARMACEUTICAL COMPOSITION :
FOR THE TREATMENT OF OBESITY
OR TO FACILITATE OR PROMOTE
WEIGHT LOSS

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date: Nov 30 '08

Respectfully submitted,


A. David Joran
Attorney for Applicant(s)
Reg. No. 37,858

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)573 -3381



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25421A	SERIAL NO. 10/791,984
	APPLICANT Coe, et al.	
	FILING DATE March 3, 2004	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6 2 3 5 7 3 0	5/01	O'Neill	514	233.2	
	6 4 1 0 5 5 0	6/02	Coe, et al.	514	232.8	
	6 4 6 2 0 3 5	10/02	Coe	514	183	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
9 8 1 8 7 9 8	10/97	PCT				
9 9 3 5 7 3 1	07/99	PCT				
9 9 5 5 6 9 0	04/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1.	Pertwee, R. G.; Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations; Exp. Opin. Invest. Drugs, 9(7) 1553-1571 (2000).
2.	Ming, et al.; Nicotine, Body Weight and Potential Implications in the Treatment of Obesity; Medicinal Chemistry (3) 899-919 (2003).
3.	Lippiello, et al.; The Binding of L ³ H]Nicotine to a Single Class of High Affinity Sites in Rat Brain Membranes; (3) 448-454 (1986).
4.	Anderson, et al.; Nicotinic Receptor Binding of [³ H]cytisine, [³ H]nicotine and [³ H]methylcarbamylcholine in rat brain; European Journal of Pharmacology 253; 261-267 (1994).
5.	Bass, et al.; Identification and Characterization of Novel Somatostatin Antagonists; Molecular Pharmacology; 50: 709-715 (1996).
6.	Smith, P.B., et al.; The Pharmacological Activity of Anandamide, a Putative Endogenous Cannabinoid, in Mice; Pharmacol. Pharmacol. Exp. Ther.; 270 (1); 219-227 (1994).
7.	Wiley, et al.; Discriminative Stimulus Effects of Anandamide in Rats; European Journal of Pharmacol.; 276; 49-54 (1995).
8.	Lumeng, et al.; Different Sensitivities to Ethanol in Alcohol-Preferring and -Nonpreferring Rats; Pharmacol. Bioschem. & Behavior; 16; 125-130 (1982).
9.	Middaugh, et al; Ethanol Consumption by C57BL/6 Mice: Influence of Gender and Procedural Variables; Alcohol; 17 (3); 175-183 (1999).
10.	Le, et al.; Alcohol Consumption by C57BL/6, BALB/c, and DBA/2 Mice in a Limited Access Paradigm; Pharmacol. Biochem. And Behavior; 47; 375-378 (1994).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.